Healthcare provider profile · identity verified

Dileema Kalansuriya

Internal Medicine · SOUTHBURY, CT · NPI 1972785608

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	670	201
Levothyroxine Sodium	Levothyroxine Sodium	426	121
Amlodipine Besylate	Amlodipine Besylate	374	112
Lisinopril	Lisinopril	250	72
Rosuvastatin Calcium	Rosuvastatin Calcium	225	77
Gabapentin	Gabapentin	219	56
Sertraline Hcl	Sertraline Hcl	197	58
Metformin Hcl	Metformin Hcl	192	66
Losartan Potassium	Losartan Potassium	185	58
Hydrochlorothiazide	Hydrochlorothiazide	176	59
Ozempic	Semaglutide	168	27
Alendronate Sodium	Alendronate Sodium	159	56
Albuterol Sulfate Hfa	Albuterol Sulfate	147	67
Simvastatin	Simvastatin	143	42
Metoprolol Succinate	Metoprolol Succinate	142	49
Trazodone Hcl	Trazodone Hcl	116	41
Omeprazole	Omeprazole	111	35
Alprazolam	Alprazolam	110	36
Pantoprazole Sodium	Pantoprazole Sodium	107	34
Famotidine	Famotidine	95	25
Jardiance	Empagliflozin	95	28
Pravastatin Sodium	Pravastatin Sodium	84	26
Metoprolol Tartrate	Metoprolol Tartrate	82	21
Bupropion Xl	Bupropion Hcl	78	20
Escitalopram Oxalate	Escitalopram Oxalate	78	25
Synthroid	Levothyroxine Sodium	72	20
Tamsulosin Hcl	Tamsulosin Hcl	69	21
Furosemide	Furosemide	68	31
Allopurinol	Allopurinol	62	18
Ezetimibe	Ezetimibe	61	20
Eliquis	Apixaban	60	15
Montelukast Sodium	Montelukast Sodium	56	20
Prednisone	Prednisone	55	39
Hydroxyzine Hcl	Hydroxyzine Hcl	53	17
Lorazepam	Lorazepam	50	15
Citalopram Hbr	Citalopram Hydrobromide	49	14
Glipizide Er	Glipizide	49	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	49	13
Zolpidem Tartrate	Zolpidem Tartrate	48	13
Buspirone Hcl	Buspirone Hcl	45	suppressed
Potassium Chloride	Potassium Chloride	45	14
Meloxicam	Meloxicam	44	23
Metformin Hcl Er	Metformin Hcl	44	16
Mirtazapine	Mirtazapine	43	13
Atenolol	Atenolol	40	15
Azithromycin	Azithromycin	40	34
Prolia	Denosumab	40	29
Fluticasone Propionate	Fluticasone Propionate	38	12
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	35	suppressed
Duloxetine Hcl	Duloxetine Hcl	35	11
Fluoxetine Hcl	Fluoxetine Hcl	34	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	34	29
Oxybutynin Chloride Er	Oxybutynin Chloride	34	suppressed
Ibandronate Sodium	Ibandronate Sodium	32	11
Carvedilol	Carvedilol	31	suppressed
Meclizine Hcl	Meclizine Hcl	30	20
Tramadol Hcl	Tramadol Hcl	30	suppressed
Paroxetine Hcl	Paroxetine Hcl	29	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	28	suppressed
Celecoxib	Celecoxib	28	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	28	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	28	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	27	23
Nystatin	Nystatin	27	12
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	27	26
Amitriptyline Hcl	Amitriptyline Hcl	26	suppressed
Finasteride	Finasteride	26	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	25	16
Quetiapine Fumarate	Quetiapine Fumarate	25	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	25	22
Clonazepam	Clonazepam	24	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	24	suppressed
Bupropion Hcl	Bupropion Hcl	23	suppressed
Propranolol Hcl	Propranolol Hcl	23	suppressed
Valsartan	Valsartan	23	suppressed
Clopidogrel	Clopidogrel Bisulfate	22	suppressed
Mounjaro	Tirzepatide	21	suppressed
Myrbetriq	Mirabegron	21	suppressed
Ramipril	Ramipril	21	suppressed
Ventolin Hfa	Albuterol Sulfate	21	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	20	suppressed
Folic Acid	Folic Acid	19	suppressed
Lovastatin	Lovastatin	19	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	19	suppressed
Warfarin Sodium	Warfarin Sodium	19	suppressed
Breo Ellipta	Fluticasone/Vilanterol	18	suppressed
Cephalexin	Cephalexin	18	14
Januvia	Sitagliptin Phosphate	18	suppressed
Entresto	Sacubitril/Valsartan	17	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	17	suppressed
Chlorthalidone	Chlorthalidone	16	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	16	suppressed
Oxycodone Hcl	Oxycodone Hcl	16	suppressed
Ranolazine Er	Ranolazine	16	suppressed
Telmisartan	Telmisartan	16	suppressed
Tradjenta	Linagliptin	16	suppressed
Diazepam	Diazepam	15	suppressed
Fenofibrate	Fenofibrate,micronized	15	suppressed
Methocarbamol	Methocarbamol	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Tresiba Flextouch U-200	Insulin Degludec	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	14	13
Trulicity	Dulaglutide	14	suppressed
Valacyclovir	Valacyclovir Hcl	14	suppressed
Baclofen	Baclofen	13	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Oxycontin	Oxycodone Hcl	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	12	suppressed
Amoxicillin	Amoxicillin	12	11
Ibuprofen	Ibuprofen	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Amiodarone Hcl	Amiodarone Hcl	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error